08 June 2017
: Case report
Levamisole-Induced Leukocytoclastic Vasculitis with Negative Serology in a Cocaine User
Patient complains / malpractice, Unexpected drug reaction , Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Mashal Salehi1ABCDEFG*, Michael P. Morgan1ABEG, Abigail Gabriel1BDGDOI: 10.12659/AJCR.903917
Am J Case Rep 2017; 18:641-643
Abstract
BACKGROUND: Levamisole is a common adulterant of cocaine. It can cause agranulocytosis and cutaneous vasculitis that can possibly lead to cutaneous necrosis. In all reported cases of levamisole-induced vasculitis, it has been described as a clinical syndrome characterized by a constellation of typical clinical features and a positive serum serology for ANCA levels, especially very high-titer p-ANCA levels, in the background of cocaine abuse. However, patients may have a negative serology and here, we present the first such case.
CASE REPORT: A 58-year-old African American man with a history of polysubstance abuse, 4 days after last cocaine use, presented with sudden onset of painful pruritic rash and polyarthralgias. He was found to have normal vital signs, with bilateral tender knees and erythematous-purplish maculopapular lesions involving the abdomen and the left thigh. Laboratory work-up was significant for elevated CRP, negative c-ANCA, p-ANCA ANA, and RA levels, and a positive urine toxicology for cocaine. Urine analysis by high-performance liquid chromatography was positive for levamisole. Ultimately, a final diagnosis was made by skin biopsy, which revealed findings suggestive of leukocytoclastic vasculitis.
CONCLUSIONS: Cutaneous leukocytoclastic vasculitis can be caused by levamisole, which is used as an adulterant in cocaine. Most cases are associated with positive ANCA levels; however, a negative serology is also a possibility.
Keywords: Cocaine, Levamisole, Vasculitis, Leukocytoclastic, Cutaneous
SARS-CoV-2/COVID-19
29 March 2023 : Editorial
Med Sci Monit In Press; DOI: 10.12659/MSM.940519
21 March 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938730
21 March 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938659
22 February 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938732
In Press
31 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938131
30 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939200
30 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939365
28 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939387
Most Viewed Current Articles
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
07 Dec 2021 : Case report
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347